Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Protocol of a randomized controlled trial investigating the effectiveness of Recovery-focused Community support to Avoid readmissions and improve Participation after Stroke (ReCAPS).

International journal of stroke : official journal of the International Stroke Society·2021

Same author

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration.

Stroke·2021

Same author

Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study.

Neuroepidemiology·2021

Same author

Ischemic Events After Intracerebral Hemorrhage: A New Target for Secondary Prevention.

JAMA neurology·2021

Same author

Secondary Prevention of Stroke: Study Protocol for a Telehealth-Delivered Physical Activity and Diet Pilot Randomized Trial (ENAbLE-Pilot).

Cerebrovascular diseases (Basel, Switzerland)·2021

Same author

Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation.

International journal of molecular sciences·2021

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiplatelet therapy for stroke prevention.

Graeme J Hankey¹

¹Consultant Neurologist and Head of Stroke Unit, Department of Neurology, Royal Perth Hospital, 197 Wellington Street, Perth, Western Australia 6001, Australia. gjhankey@cyllene.uwa.edu.au

Current Atherosclerosis Reports

|January 5, 2008

Summary

This summary is machine-generated.

For stroke prevention, combining clopidogrel with aspirin showed no added benefit over aspirin alone. However, adding extended-release dipyridamole to aspirin improved outcomes in certain ischemic stroke patients.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Experiment Videos

Last Updated: Jul 8, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Area of Science:

Neurology
Cardiology
Pharmacology

Background:

Atherothrombotic events pose a significant risk for major vascular events.
Optimal antiplatelet and anticoagulation therapies for stroke prevention are under continuous investigation.

Purpose of the Study:

To evaluate the efficacy of combination antiplatelet therapies versus standard treatments for stroke prevention.
To compare oral anticoagulation with aspirin in patients with recent cerebral ischemia.

Main Methods:

Review of recent clinical trials on antiplatelet therapy and oral anticoagulation for stroke prevention.
Analysis of combination therapy (clopidogrel plus aspirin) versus aspirin alone.
Comparison of oral anticoagulation versus aspirin in atrial fibrillation and cerebral ischemia patients.
Evaluation of aspirin plus extended-release dipyridamole versus aspirin alone.

Main Results:

Clopidogrel plus low-dose aspirin was not superior to low-dose aspirin alone for preventing major vascular events in high-risk patients.
Oral anticoagulation was not more effective than aspirin alone in patients with recent cerebral ischemia of presumed arterial origin.
Aspirin combined with extended-release dipyridamole demonstrated greater efficacy than aspirin alone in patients with recent cerebral ischemia of presumed arterial origin.

Conclusions:

Combination therapy with clopidogrel and aspirin does not offer additional long-term benefits for major vascular event prevention compared to aspirin alone.
Extended-release dipyridamole in combination with aspirin shows promise for preventing recurrent atherothrombotic ischemic stroke.
Further large-scale trials are ongoing to compare clopidogrel with aspirin plus extended-release dipyridamole.